TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04417088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
Study: NCT02617784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir will be given as marketed oral suspension, 30 mg after HD or CAPD treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir will be given as marketed oral suspension, 30 mg after HD or CAPD treatment.
Study: NCT00801918

Intervention type: DRUG
Group type: OTHER
Intervention: Denileukin Diftitox
Description: Denileukin Diftitox: 18 mcg/kg/day: days 1-5 in cycles 1,2,3,4
Study: NCT04417088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate BBBD
Description: BBB opening via Exablate Neuro Type 2 system with microbubble resonators.
Study: NCT04318431

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Data collection and rhinopharyngeal swab
Description: Testing for SARS -Cov2 and other respiratory pathogens by PCR via nasopharyngeal swabbing and IgM/IgG rapid serology
Study: NCT02865148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: CBT-based protocol tailored to advanced breast cancer patients with a focus on managing a broad array of symptoms including psychological distress, pain, and fatigue. Important features of the protocol are: 1) a unique motivational interviewing component in the first session that will focus on patients' motivation for engaging in the protocol, confidence (i.e., self-efficacy) to learn new strategies, and potential barriers to adopting recommendations for lifestyle change; and 2) protocol that targets multiple symptoms, and 3) adapted to meet the unique needs of advanced breast cancer patients.
Study: NCT01868373

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Microbiota Transplantation (FMT)
Description: Active therapy
Study: NCT00801918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide
Description: Denileukin Diftitox: 18 mcg/kg/day days 1-2 in cycles 5 and 6 Ifosfamide: 3000mg/m²/IV/d X 3 days + Mesna 3000 mg/m2/d X 3 days Carboplatin: 635mg/m2/d X 1 day Etoposide: 100mg/m2/d X 3 days
Study: NCT00697073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients \> 45 kg/99 lbs: idebenone 2250 mg/day
Study: NCT02935101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: formulated for oral administration. encapsulated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Prednisolone)
Description: Sugar pill manufactured to mimic Prednisolon 10mg capsules
Study: NCT02379923

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crossing of Coronary Artery CTO
Description: Standard angiographic procedures will be followed for this study. The primary objective of this trial is to evaluate confirmation of placement of any guidewire beyond the chronic total occlusion (CTO) in the true vessel lumen in patients in which at least one Asahi series of guidewires and/or Corsair microcatheter were used.~Procedure success will be defined as angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital MACE.~Other Name: ASAHI Corsair Microcatheter, ASAHI PTCA Guide Wires
Study: NCT01498835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Patients will receive Sunitinib daily for 2 weeks prior to and then concurrently with irradiation as neoadjuvant treatment. Radiotherapy will be given as intensity modulated radiation therapy with a total dose of 50.4Gy in 28 fractions to each patient (5 1/2 weeks).~Sunitinib will be given in two dose levels. The first dose level will be 25mg Sunitinib per os daily. The second dose level will be 37.5mg sunitinib per os daily. A dose modification schedule according to a 3+3 design will be applied for patient accrual.
Study: NCT00697385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclokapron
Description: (2) 500mg tablets taken by mouth every 6-8 hours
Study: NCT03110510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 5FU 400mg/m2 bolus and then 2400mg/m2, continuous infusion D1-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Irinotecan 180 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Leucovorin 200 mg/m2
Study: NCT04698447

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_MetS
Description: 20 eligible subjects with the metabolic syndrome (MetS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months and as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (without any active ingredients)
Description: 20 eligible subjects with the metabolic syndrome will take placebo in a spray-dried formulation (without any active ingredients) directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Natural supplement containing nanovesicles delivered from Citrus Limon (L.) juice_HS
Description: 20 eligible healthy subjects (HS) will take natural supplement containing a spray-dried formulation of citraVes™, directly in the mouth, without water, to be dissolved preferably under the tongue, at a stable dose of one sachet a day (1000 mg/day) for 6 months, maintained at fixed doses for the entire study.
Study: NCT05562856

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: surface pre-reacted glass filler coating material
Description: the ability to improve the aesthetic appearance (masking) and caries lesion state of the WSLs
Study: NCT00467610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panhematin
Study: NCT03815617

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zircombi
Description: Twenty-five IBS patients (Rome IV criteria) (M:F= 8:17; age 48 yrs ± 11 SD) were enrolled and randomized to treatment or placebo in a a crossover randomized double-blind two-block placebo-controlled trial. Abdominal pain and bloating, intestinal habits, severity of disease, intestinal permeability, and intestinal microbiota were performed at the different time points.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given as comparable packets. Same duration.
Study: NCT02521571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resiliance Alliance
Description: The intervention is 6 months long \& is delivered through weekly sessions held in the participating child protective offices. The sessions follow a 4-week cycle with the participants changing each week of the cycle: (1) CPS alone, by units; (2) CPS/Supervisor units; (3) Child Protective Manager and CPS/Supervisor units; and (4) CPSs \& Supervisors/Managers separately.~Participating staff are introduced to a resilience-related topic or skill, and receive a brief didactic training on that topic. Staff then engage in a group activity, which is designed to help them apply the new topic or skill to the workplace. Each module wraps up with a relaxation or exercise to help staff transition back into their work responsibilities; the facilitator can pick among the selection provided based on their sense of what would be helpful for the group. Staff are also given handouts and activities to do during the week.
Study: NCT02521571

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Secondary traumatic stress training
Description: These trainings will take place in two parts (for a total of 3 hours) and include an overview of secondary traumatic stress and its impact on child welfare staff, and some strategies staff can use to protect themselves from STS - essentially a summary version of what the intervention group will receive over the 24 weeks of the intervention. The investigators consider this training to represent treatment as usual, as from our experience it is often how child welfare agencies address the issue of secondary traumatic stress among their staff.
Study: NCT01539798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral saline
Description: Ingestion of 2 L of 0.9% saline solution over 1h

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous saline
Description: Infusion of 2L of 0.9% saline solution over 1h
Study: NCT00986479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: Single IV infusion of 150 mg AZD6765.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to AZD6765
Description: Single IV infusion of Placebo to AZD6765
Study: NCT01304160

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy
Description: 30Gray in 5 fractions
Study: NCT05562856

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: surface pre-reacted glass filler coating material
Description: the ability to improve the aesthetic appearance (masking) and caries lesion state of the WSLs

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: surface pre-reacted glass filler coating material
Description: the ability to improve the aesthetic appearance (masking) and caries lesion state of the WSLs
Study: NCT02598973

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Aerobic walking
Study: NCT00997659

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chromium picolinate
Description: 1000 mg per day
Study: NCT04507269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIR-2218
Description: VIR-2218 given by subcutaneous injection
Study: NCT04533685

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Appointment flu vaccine reminders
Description: Patients receive modified pre-appointment reminders for upcoming scheduled appointments that include language encouraging patients to ask the provider for the flu vaccine

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-Appointment flu vaccine reminders
Description: Patients receive modified pre-appointment reminders for upcoming scheduled appointments that include language encouraging patients to ask the provider for the flu vaccine
Study: NCT01225107

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry Extract
Description: 500mg TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inert Placebo Capsule
Description: Inert substance, 3 times per day in capsule form
Study: NCT02035475

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intuitive Vessel Sealer
Description: Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intuitive Vessel Sealer
Description: Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
Study: NCT00355654

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DT5aP-IPV-Hib 5-component Pertussis vaccine
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DT3aP-HBs-IPV
Description: 0.5 mL, IM
Study: NCT04307914

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: The current standard of care for patients with uncomplicated painful bone metastases is palliative locoregional external beam radiotherapy, often in combination with systemic therapy and analgesics.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiotherapy
Description: The current standard of care for patients with uncomplicated painful bone metastases is palliative locoregional external beam radiotherapy, often in combination with systemic therapy and analgesics.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR-HIFU
Description: MR-HIFU is a non-invasive treatment modality that delivers acoustic energy to heat tissue to ablative temperatures of more than 60°C. The combination of focused ultrasound with magnetic resonance imaging (MRI) enables physicians to perform localized tumor tissue ablation, with real-time temperature monitoring using magnetic resonance (MR) thermometry.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MR-HIFU
Description: MR-HIFU is a non-invasive treatment modality that delivers acoustic energy to heat tissue to ablative temperatures of more than 60°C. The combination of focused ultrasound with magnetic resonance imaging (MRI) enables physicians to perform localized tumor tissue ablation, with real-time temperature monitoring using magnetic resonance (MR) thermometry.
Study: NCT04595344

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Listening to Pure Binaural Beats
Description: The patients in DCG ((binaural beat group) ) and USRG (binaural beat group) listened to binaural beats.The binaural beats were produced using a software program (Audacity®, version win. 2.3.2, 2019 Audacity Team) at frequency of 10 Hz (a tone of 200 Hz in the right ear and a tone of 210 Hz in the left ear). The binaural beats that the patients in DCG-1 and USRG-1 listened to were pure frequencies, with no background music or waves.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Listening to Pure Binaural Beats
Description: The patients in DCG ((binaural beat group) ) and USRG (binaural beat group) listened to binaural beats.The binaural beats were produced using a software program (Audacity®, version win. 2.3.2, 2019 Audacity Team) at frequency of 10 Hz (a tone of 200 Hz in the right ear and a tone of 210 Hz in the left ear). The binaural beats that the patients in DCG-1 and USRG-1 listened to were pure frequencies, with no background music or waves.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Listening to classical music
Description: The patients in DCG (classical music group) and USRG (classical music group) listened to classical music.The classical music that those in DCG-2 and USRG-2 listened to was Mozart's 40th Symphony.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Listening to classical music
Description: The patients in DCG (classical music group) and USRG (classical music group) listened to classical music.The classical music that those in DCG-2 and USRG-2 listened to was Mozart's 40th Symphony.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No audio only headphone
Description: The patients in DCG (placebo group) and USRG (placebo group) sat in a quiet room with headphones on but no audio playing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No audio only headphone
Description: The patients in DCG (placebo group) and USRG (placebo group) sat in a quiet room with headphones on but no audio playing
Study: NCT04507269

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline given by subcutaneous injection
Study: NCT02942875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mirror therapy
Description: During MT, subjects will sit in front of a table on which a mirror will be placed vertically in the space ipsilateral to the paretic upper limb with its reflective surface facing the unaffected upper limb. The subjects are required to look at the mirror to observe the reflective image of the unaffected arm from shoulder to the hand, while it is performing certain designated movements. At the same time, the affected arm will be required to follow the unaffected arm to practice the same movements.~The upper limbs movements during the 30-min MT session are open and close of grasp; wrist flexion and extension; forearm supination and pronation; elbow flexion and extension; shoulder flexion and extension. A total of 120 repetitions for each action will be practiced.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control therapy
Description: Control group subjects undergo the same bilateral upper limbs exercise protocol without mirror
Study: NCT02341105

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Pulmonary vein isolation by catheter ablation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: antiarrhythmic therapy using Amiodarone
Study: NCT00992329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ciprofloxacin
Description: ciprofloxacin 200mg tablet (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Description: ciprofloxacin 200mg tablet (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Description: ciprofloxacin 200mg tablet (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin
Description: ciprofloxacin 200mg tablet (single dose)
Study: NCT02185846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DYNABAC 250 MG ENTERIC COATED TABLET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIRITHROMYCIN 500 MG ENTERIC COATED TABLET
Study: NCT04292392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preop ACB, followed by Intra-articular block during TKA surgery
Description: Preoperative ACB (adductor canal block), followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preop ACB+IPACK block
Description: Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preop ACB+IPACK block, followed by Intra-articular block during TKA surgery
Description: Preoperative ACB (adductor canal block) and IPACK (Interspace between the Popliteal Artery and the Capsule of the posterior Knee) block, followed by a local anesthetic injection during surgery, which is comprised of the following agents and amounts:~* Ropivacaine 5mg/ml (49.25ml)~* Epinephrine 1mg/ml (0.5ml)~* Ketorolac 30mg/ml (1ml)~* Clonidine 0.1mg/ml (0.8ml)~* Saline 48.45ml
Study: NCT02671773

Intervention type: DRUG
Intervention: Inhaled corticosteroid dose/type

Intervention type: DRUG
Intervention: Inhaled corticosteroid dose/type

Intervention type: DRUG
Intervention: Inhaled corticosteroid dose/type
Study: NCT03833583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix Medical mini-CT tDCS stimulator
Description: Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Soterix Medical mini-CT tDCS stimulator
Description: Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks
Study: NCT04229017

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Cervical Discectomy and Fusion
Description: Anterior Cervical Decompression and Fusion (ACDF) is a standard of care procedure that is performed using standard instruments and completed with an allograft interbody implant and anterior plate.
Study: NCT00526604

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: work related rehabilitation
Description: The workplace intervention includes two steps:~Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.~Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks.
Study: NCT02466373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml
Description: clonidine intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml
Description: clonidine intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml
Description: clonidine intravenous
Study: NCT01624051

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard dosing method arm: Cisplatin (chemotherapy) dosing based on body surface area
Description: Cisplatin dosing calculated at the rate of 75 mg/m2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental dosing method arm: Cisplatin (chemotherapy) dosing based on individual lean body mass
Description: Cisplatin dosing calculated at the rate of 3.10 mg/kg lean body mass
Study: NCT03300323

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: IV fluid challenge administration
Description: Administration of an intravenous fluid challenge to assess for fluid responsiveness

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: IV fluid challenge administration
Description: Administration of an intravenous fluid challenge to assess for fluid responsiveness
Study: NCT04575844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 24 weeks of Liraglutide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 24 weeks of Exercise training

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide + Exercise training
Description: 24 weeks of Liraglutide + Exercise training
Study: NCT00973271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 290 mg DCCR
Description: 290 mg diazoxide choline
Study: NCT04614077

Intervention type: OTHER
Intervention: ex vivo organ bath testing, preservation of vein sections without contact to patient
Description: 1 piece of vein is separated during surgical bypass procedure, then randomized and put ex vivo in two solutions: saline and specific solution, then tested in the organ bath

Intervention type: OTHER
Intervention: ex vivo organ bath testing, preservation of vein sections without contact to patient
Description: 1 piece of vein is separated during surgical bypass procedure, then randomized and put ex vivo in two solutions: saline and specific solution, then tested in the organ bath
Study: NCT00875147

Intervention type: DRUG
Intervention: bevacizumab
Description: Neoadjuvant chemotherapy with bevacizumab